Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP

PURPOSE: Alectinib is an anaplastic lymphoma kinase (ALK) –specific kinase inhibitor that seems to be effective against non–small-cell lung cancer (NSCLC) with a variety of ALK mutations. The primary analysis of AF-001JP reported a promising overall response rate. To assess progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Tomohide, Kiura, Katsuyuki, Seto, Takashi, Nakagawa, Kazuhiko, Maemondo, Makoto, Inoue, Akira, Hida, Toyoaki, Yoshioka, Hiroshige, Harada, Masao, Ohe, Yuichiro, Nogami, Naoyuki, Murakami, Haruyasu, Kuriki, Hiroshi, Shimada, Tadashi, Tanaka, Tomohiro, Takeuchi, Kengo, Nishio, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455704/
https://www.ncbi.nlm.nih.gov/pubmed/28296581
http://dx.doi.org/10.1200/JCO.2016.70.5749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455704/
https://www.ncbi.nlm.nih.gov/pubmed/28296581
http://dx.doi.org/10.1200/JCO.2016.70.5749

Ejemplares similares